FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression | Eli Lilly and Company

INDIANAPOLIS, March 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ — The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax(R) (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company (NYSE: LLY) announced today. Symbyax is now the first drug approved by the FDA for the acute treatment of treatment-resistant depression (TRD). “Living with major depressive disorder...

READ MORE FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression | Eli Lilly and Company

New Hope for Depression on the Horizon

The FDA accepts a New Drug Application for novel antidepressant. NEWS BRIEF The US Food and Drug Administration has reviewed and accepted the New Drug Application (NDA) for LY03005, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI). Developed under Luye Pharma’s New Chemical and Therapeutic Entities Research and Development platform, the company has obtained patents covering the chemical compound, crystal form, and...

READ MORE New Hope for Depression on the Horizon

Global Antidepressant Drugs Market Expected to Witness a CAGR of 2.2%

Bangalore, India, September 28, 2018: With its recently published study “Antidepressant Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast up to 2024”, Infoholic Research forecasts that the global market for antidepressant drugs will grow, owing to the growing aging population and increasing prevalence of depression. Supportive initiatives from the government & other organizations and increasing clinical trials are...

READ MORE Global Antidepressant Drugs Market Expected to Witness a CAGR of 2.2%

Generated by Feedzy